Valuation: Talphera, Inc.

Market Cap 55.53M 48.55M 44.61M 41.59M 78.88M 5.29B 80.07M 536M 208M 2.6B 208M 204M 8.96B P/E 2026 *
-4.28x
P/E 2027 * -3.82x
Enterprise Value 55.53M 48.55M 44.61M 41.59M 78.88M 5.29B 80.07M 536M 208M 2.6B 208M 204M 8.96B EV / Sales 2026 *
-
EV / Sales 2027 * 278x
Free-Float
78.58%
Yield 2026 *
-
Yield 2027 * -
1 day+1.90%
1 week+3.88%
Current month+3.88%
1 month+33.75%
3 months+48.14%
6 months-7.76%
Current year-6.14%
1 week 1
Extreme 1
1.1
1 month 0.79
Extreme 0.792
1.13
Current year 0.69
Extreme 0.6866
1.29
1 year 0.38
Extreme 0.38
1.57
3 years 0.38
Extreme 0.38
1.61
5 years 0.38
Extreme 0.38
31
10 years 0.38
Extreme 0.38
115
Manager TitleAgeSince
Chief Executive Officer 58 2017-03-05
Director of Finance/CFO 56 2017-07-31
Chief Tech/Sci/R&D Officer - 2024-09-30
Director TitleAgeSince
Director/Board Member 60 2006-07-31
Director/Board Member 72 2010-01-31
Chairman 75 2013-02-10
Date Insider Type Main position Quantity % Market Cap.
06-21Free

Chairman

35,800 0.0715%
06-21Free

Director

35,800 0.0715%
06-21Free

Director

35,800 0.0715%
Change 5-day change 1-year change 3-year change Capi.($)
+1.90%+3.88%+137.25%-1.83% 55.53M
+3.34%+0.70%+60.09%+13.32% 320B
-1.25%0.00%+30.92%-1.55% 72.44B
+3.17%+5.99%+47.13%+115.43% 9.42B
+1.24%+4.51%+5.99%+0.26% 8.65B
+8.48%+25.95%+25.73%+38.15% 4.52B
-0.46%+3.98%-5.69%+3.61% 4.41B
+0.43%+6.02%-33.90%+24.44% 3.43B
+1.35%+2.58%+50.25%+60.70% 2.79B
-1.28%+7.61%+15.27%-23.79% 2.19B
Average +1.69%+2.79%+33.30%+22.87% 42.79B
Weighted average by Cap. +2.47%+2.85%+51.69%+13.16%

Financials

2026 *2027 *
Net sales - 200K 175K 161K 150K 284K 19.04M 288K 1.93M 750K 9.36M 751K 735K 32.26M
Net income -17.96M -15.7M -14.43M -13.45M -25.52M -1.71B -25.9M -173M -67.36M -841M -67.43M -65.98M -2.9B -20.15M -17.61M -16.18M -15.09M -28.61M -1.92B -29.05M -194M -75.53M -943M -75.62M -73.99M -3.25B
Net Debt - -
Logo Talphera, Inc.
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.
Employees
12
Date Price Change Volume
26-07-02 US$1.070 +1.90% 427,101
26-07-01 US$1.050 +1.94% 365,615
26-06-30 US$1.030 -1.90% 291,840
26-06-29 US$1.050 +1.94% 94,022
26-06-26 US$1.030 -3.74% 270,967
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.070USD
Average target price
3.167USD
Spread / Average Target
+195.95%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TLPH Stock